Life Genomics will distribute Luxia's 1test1 test in Sweden, Denmark, Finland, Iceland, and Norway. The test leverages sequencing technology to analyze the 16s RNA gene.
The diagnostic test, IBS-smart, which measures antibodies that are elevated in patients with post-infectious irritable bowel syndrome, is already available to physicians in the US.
The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.
The device is designed to be used with the Inova Diagnostics' Quanta Flash assay for the detection of fecal calprotectin in human stool samples.
The assay can be used in conjunction with other laboratory and clinical findings to differentiate IBD from irritable bowel syndrome, the firm said.
The fully automated, random access calprotectin assay can help clinicians differentiate irritable bowel disease from irritable bowel syndrome.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.